We investigated toxicity and efficacy of in vivo T-cell depletion with anti-thymocyte globulin (ATG) as part of an intensified myeloablative conditioning regimen followed by allogeneic stem cell transplantation in patients with advanced multiple myeloma. The conditioning regimen consisted of modified total body irradiation, busulfan and cyclophosphamide (n ¼ 15) or in the case of prior doselimiting radiotherapy of busulfan and cyclophosphamide (n ¼ 3). The median age was 44 years (range, 29-53) and the median time from diagnosis to transplant was 12 months (range, 6-144). Grade II-IV acute graft-versushost disease (GvHD) occurred in six patients (35%). Severe grade III/IV GvHD developed in one patient (6%). Three patients died of therapy-related causes (17%). A complete remission (CR) with negative immunofixation after allogeneic transplantation was seen in eight of the evaluable patients (53%). After a median follow-up of 41 months (range, 8-84), the estimated overall survival at 6 years for all patients is 77% (CI 95%: 58-96%). The estimated progression-free survival at 6 years for all patients is 31% (CI 95%: 2-59%) and 46% (CI 95%: 9-83%) for patients with CR. In vivo T-cell depletion with ATG resulted in a low rate of severe GvHD with low treatment-related mortality, and a substantial number of long-term survivors. Bone Marrow Transplantation (2003) 31, 973-979. doi:10.1038/sj.bmt.1704049 Keywords: anti-thymocyte-globulin; multiple myeloma; stem cell transplantation; total marrow irradiation Allogeneic stem cell transplantation is a potential curative approach in patients with multiple myeloma. In a retrospective study of the EBMT, 42% of the patients were disease-free 5 years after allogeneic transplantation.
stem cell transplantation; total marrow irradiation Allogeneic stem cell transplantation is a potential curative approach in patients with multiple myeloma. In a retrospective study of the EBMT, 42% of the patients were disease-free 5 years after allogeneic transplantation. 1 The advantage of allogeneic stem cells compared to autologous stem cells is a direct antitumour activity through the graft vs myeloma effect by allogeneic immunocompetent T cells. [2] [3] [4] However, in a retrospective case matched study, the transplant-related morbidity and mortality were up to 40%, resulting in a worse outcome compared to autologous transplantation, despite a lower progression rate. 5 For this reason, efforts were made to improve the results by better selection of patients and earlier timing of transplantation, 6 by using peripheral blood progenitor cells (PBSCs) as stem cell source 7 and to decrease the transplant-related mortality by using more effective methods to prevent severe graftversus-host disease (GvHD). 8, 9 Recently, the EBMT registry reported a lower transplant-related mortality of 30% for patients transplanted after 1995. 10 A lower treatment-related mortality has been reported for so-called nonmyeloablative or dose-reduced conditioning regimens in patients with multiple myeloma. [11] [12] [13] To reduce the treatment-related mortality, we investigated in vivo T-cell depletion with anti-thymocyte globulin (ATG) as part of the conditioning regimen consisting of total marrow irradiation, busulfan and cyclophosphamide or of busulfan and cyclophosphamide alone in allogeneic stem cell transplantation with HLA-identical donors in patients with multiple myeloma. Observations in unrelated stem cell transplantation showed that ATG as part of the conditioning regimen resulted in a low incidence of severe acute and chronic GvHD without obvious increase of relapse rate. 14, 15 
Study objective
The primary objectives of the study were to evaluate, acute and chronic GvHD and the treatment-related mortality of an intensified myeloablative conditioning regimen plus pretransplant ATG followed by allogeneic stem cell transplantation. The secondary objective was to evaluate the response rate and the relapse rate.
Study design
Patients with advanced multiple myeloma stage II/III, 18-55 years of age, and an HLA-identical donor were eligible for the study protocol. To be included patients were required to have sufficient cardiac function, creatinine clearance greater than 30 ml/min, lung diffusion capacity of at least 50% and liver transaminases not greater than three times the upper limit of normal. Written informed consent was received from each patient, and the study was approved by the local Ethics Committee. The conditioning regimen was as follows:
In the case of prior dose-limiting radiotherapy the regimen was changed as follows:
This modified total body irradiation regimen was delivered by a linear accelerator in 1.5 Gy fractions twice daily over 3 days at a dose rate of 0.12 Gy/min with 90% lung and liver shielding (day À9 to À7). The minimum interval between fractions was 6 h. After radiation, electron beams (1.5 Gy) were applied to rib areas that were shielded. Busulfan was administered orally in four divided doses daily for 3 days (day À6 to À4). Owing to severe mucositis, the dose of busulfan was reduced to 9 mg/kg in the protocol. Cyclophosphamide (60 mg/kg) was given intravenously over 1 h for 2 days (day À3 and À2). To prevent busulfan-induced seizure, phenytoin was given until 2 days after stopping busulfan. Uroepithelial prophylaxis was achieved with hyperhydration and mesna. Bone marrow or peripheral blood stem cells were infused 24-48 h after the last cyclophosphamide administration (day 0). Granulocyte colony stimulating factor (G-CSF, 5 mg/kg BW) was given after allogeneic transplantation intravenously from day 1 and continued until sustained neutrophil engraftment.
Regimen-related toxicity was graded using the Bearman score. 16 The maximum score for each organ system was recorded. Attempts were made to exclude toxicities due to GvHD from the therapy-related toxicity. Veno-occlusive disease of the liver was graded according the Seattle criteria. 17 
Patients
Between 1995 and 2001, 18 patients (14 male and four female patients ) with a median age of 44 years (range, 29-53) were enrolled in this multicentre phase I/II trial. The disease status prior to allogeneic transplantation was partial remission (PR: n ¼ 14), no change (NC: n ¼ 2) and progressive disease (PD: n ¼ 2). The median number of prior chemotherapy cycles was 6 (range, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . One patient received prior high-dose chemotherapy with autologous stem cell transplantation. Six patients had prior radiation therapy and three of them were therefore not eligible for total marrow irradiation. The median b2-microglobulin serum level at diagnosis was 3.1 mg/dl (range, 1.7-11). The median time from diagnosis to transplant was 12 months (range, 6-144). The stem cell source was bone marrow in 13 patients, and peripheral blood stem cells in five patients. In all, 15 patients received conditioning with total marrow irradiation, 900 cGy given over 3 days in six fractions, followed by busulfan, 12 mg/kg (n ¼ 4) or 9 mg/kg (n ¼ 11), and cyclophosphamide (120 mg/kg), and three patients with prior radiation therapy received only busulfan (14 mg/kg) and cyclophosphamide (120 mg/kg). The characteristics of the patients are shown in Table 1 .
HLA-typing and donor matching
HLA-A and -B antigens were typed by serologic methods, HLA-DRB1 alleles were typed with sequence-specific oligonucleotide probes. Donors were required to match the recipients for the serological defined HLA-A and -B antigens as well as HLA-DRB1 alleles. In all patients, the pretransplantation lymphocyte cross match with patient sera and donor cells was performed. In all, 17 patients had an HLA-identical sibling, whereas one patient received stem cells from an unrelated donor.
Supportive care
All patients were nursed in single rooms with hepa-filtered air. Antibiotic prophylaxis consisted of ofloxacin or ciprofloxacin, and antifungal prophylaxis of fluconazole. Acyclovir was given as Herpes prophylaxis from day 1 until Allografting in multiple myeloma with ATG N Kröger et al day 180. Pneumocystis-carinii prophylaxis consisted of either of trimethoprime and sulfamethoxazole or monthly inhalation with pentamidine. Weekly monitoring of blood and urine for CMV-antigen by polymerase chain reaction (PCR) and short-term culture was carried out. In the case of repeated positivity, ganciclovir treatment was initiated.
All red blood products were irradiated before infusion, and in CMV seronegative patients only blood products from CMV-negative donors were given.
GvHD prophylaxis
Rabbit ATG (Fresenius, Bad Homburg, Germany) was given to all patients within the preparative regimen. In all, 17 patients received a dose of 30 mg/kg BW over 12 h on days À3, À2 and À1, and one patient received only a single dose of ATG, 30 mg/kg BW, on day À3, because of severe bronchospasm after the first application. Further GvHD prophylaxis consisted of cyclosporin A, 3 mg/kg, given from day À1 to 6 months post-transplantation. The dose of cyclosporin A was adjusted to serum levels. Cyclosporin A was tapered from day 84 and discontinued at day 180. Methotrexate (10 mg/m 2 ) was given on days 1, 3 and 6 posttransplantation. Patients received intravenous globulin on days 1, 7, 14, 21, 28, 56, 84 and day 120. Acute GvHD was treated with high-dose steroids, and extensive chronic GvHD with cyclosporin A and steroids. Chronic GvHD was evaluated in patients who survived at least 100 days with sustained engraftment. The standard criteria were used for grading of acute and chronic GvHD. 18 
Definition of response
Response to treatment was defined according to the EBMT/IBMTR criteria. 19 Briefly, complete remission (CR) required the disappearance of monoclonal gammopathy from serum and urine as determined by immunofixation analysis for at least 6 weeks and less than 5% plasma cells in a bone marrow aspirate. A PR was defined as 450% reduction and a minor response (MR) as 425% reduction of the paraprotein level, respectively. NC was defined as a less than 25% decrease or increase of the paraprotein. Relapse was defined as recurrence of the monoclonal protein or bone marrow plasmacytosis in case of prior CR. Progression of non-CR patients required at least a 25% increase of paraprotein or development of new bone lesions.
Statistical methods
Survival curves for disease-free survival and overall survival were estimated by the Kaplan-Meier method. The log-rank test was performed for statistical analyses for time-dependent analyses of survival, and progressionfree survival. A P-value of o0.05 was considered significant. Allografting in multiple myeloma with ATG N Kröger et al
Results

Engraftment
GvHD
No signs of acute GvHD were noted in seven patients. Four patients developed grade I acute GvHD, and grade II-IV acute GvHD occurred in six patients (25%). Severe grade III and IV GvHD was seen in only one patient (6%), who died from acute GvHD. Chronic GvHD was evaluated in 15 patients who survived day 100 post-transplantation. The incidence of chronic GvHD was 27%, and only one of these had extensive disease (7%). However, two patients who received DLI for further tumour regression developed acute GvHD grade II and III, respectively, and one of them experienced extensive GvHD, requiring further immunosuppression.
Treatment-related toxicity
Major toxicity was mucositis. Grade II according to the Bearman score was noted in 14 patients, whereas two patients experienced grade III, requiring prophylactic intubation. Both patients were treated with TMI, cyclophosphamide and busulfan (12 and 9 mg/kg, respectively). Liver toxicity grade II was seen in six patients, grade I in five patients, whereas five patients did not experience liver toxicity. One patient developed EBV-associated lymphoma, which resolved completely after anti-CD20 therapy and Tcell infusion. Three patients died of treatment-related causes: one patient died of severe GvHD grade IV, one patient, who had extensive pretreatment with melphalan (18 cycles), developed multiorgan failure on day +13, and one patient died from sepsis at day 0 of transplantation, resulting in a treatment-related mortality of 17%. Four patients developed CMV reactivity, but responded to ganciclovir. No CMV disease was observed ( Figure 1 ).
Response to transplantation
In total, 15 patients were evaluable for response. A complete response after allogeneic transplantation was seen in eight patients (53%), while seven patients (47%) achieved a PR. On an intent to treat basis, the CR rate was 44% (8/18) . Two patients with PR after allogeneic transplantation (positive immunofixation) received a donor lymphocyte infusion (1.5 Â 10 8 and 1 Â 10 7 CD3 + cells/kg BW) eight and 14 months after transplantation, respectively. Both patients developed acute (grade II or III) and chronic GvHD. Both patients converted from PR to CR, which increased the rate of CRs up to 67% (all patients 10/ 18: 55%). These two patients have been described recently. 20 Overall and progression-free survival After a median follow-up of 41 months (range, 8-84), the estimated overall survival at 6 years for all patients is 77% (CI 95%: 68-98%). The estimated progression-free survival at 6 years for all patients is 31% (CI 95%: 2-59%) and 46% (CI 95%: 9-83%) for patients with CR after allograft. In all, 13 patients are currently in CR after donor lymphocyte infusion or salvage dose-reduced allograft for disease persisting or relapsing after the original transplant. Therefore, the estimated probability of being in CR at 6 years is 62% (CI 95%: 32-94%). The Kaplan-Meier survival curves for overall and event-free survival are shown in Figures 2-4 .
Relapse-rate and treatment of relapse Another patient with chronic GvHD was not eligible for donor lymphocyte infusion and received thalidomide and achieved PR. The following four patients received donor lymphocyte infusion. One patient is too early for evaluation. A female patient received 5 Â 10 6 CD3 + cells/kg BW and achieved CR without development of GvHD. After 2 months, she progressed and received local radiotherapy and further DLI. As a result of no response to radiotherapy, two cycles of chemotherapy with VAD in combination with DLI plus GM-CSF and a-interferon were initiated. The patient experienced limited chronic GvHD and is now in good PR with only positive immunofixation in the urine. Another female patient with progress received escalating DLI (5 Â 10 6 -1 Â 10 8 CD3 + cells/kg BW) in combination with a-interferon. This patient did not show any sign of GvHD and no response. Treatment with thalidomide resulted in no change of the bone marrow infiltration and of the paraprotein. A second stem cell transplantation from her HLA-identical sibling was performed after a dosereduced conditioning with melphalan (100 mg/m 2 ) without any immunosuppression. The patient experienced acute GvHD of the skin grade II and has now been in CR for more than 2 years. A male patient received DLI twice (1 Â 10 6 and 1 Â 10 7 CD3 + cells/kg BW). Owing to no significant response after 3 months, treatment with melphalan/prednisone and thalidomide was started. A couple of weeks later, the patient developed extensive chronic GvHD and a decrease of the monoclonal band. The patient is now in CR 4 years after DLI, but has still active chronic GvHD.
Discussion
Allogeneic stem cell transplantation is probably a curative approach in the treatment of patients with multiple myeloma. Despite a higher rate of CRs and a lower rate of relapse in comparison with autologous transplantation, due to the treatment-related mortality of 35-57% reported by the EBMT, 5 by the Socie´te´Franc¸aise 21 and by the Seattle group, 22 the role of allogeneic stem cell transplantation in treatment of multiple myeloma is controversial. The high treatment-related mortality is mainly because of the heavily pretreated or refractory patients and to the development of severe GvHD. Studies with earlier transplantation, PBSC as stem cell source or T-cell depletion for GvHD prevention resulted in a lower treatment-related mortality of about 20%. 7, 9 A recently performed analysis of the EBMT also showed a lower transplant-related mortality (21% at 6 months and 30% at 2 years) for patients transplanted after 1995 in comparison with the patients transplanted before 1995 (38% at 6 months and 46% 2 years). 10 Ex vivo T-cell depletion of the graft did reduce the rate of GvHD, but resulted in a higher rate of relapse. 9, 23 Our group and others showed that ATG as part of the conditioning regimen resulted in a low incidence of severe GvHD without obvious increase of relapse in unrelated stem cell transplantation. 14, 15, 24, 25 Therefore, the major aim of our present study was to lower treatment-related mortality by avoiding severe GvHD. We incorporated ATG in the preparative regimen of modified total body irradiation, busulfan and cyclophosphamide or to busulfan and cyclophosphamide. ATG consists of rabbit immunoglobulins. After immunization with cells from a T lymphoblast cell line (Jurkat T-cell line), this highly purified immunoglobulin consists of antibodies exerting a direct effect towards lymphoblastic T cells resulting in T-cell depletion via opsonization and lysis following complement activation. Pharmacokinetic studies of ATG using ELISA techniques and an inhibitory effect on phytohaemagglutinin-induced blastogenesis showed a dose-dependent effect of ATG. Rabbit IgG was detectable at least 4 weeks after administration in the recipient of bone marrow, and the effect of the phytohaemagglutinin response on normal mononuclear cells lasted up to 4 days post-transplantation. 26 Therefore, the effect of ATG as part of the pretransplant conditioning regimen is likely to be an in vivo T-cell effect on the donor bone marrow. The incidence of grade II-IV acute GvHD in our study was 35% and severe grade III/IV GvHD was seen in only one patient (6%). The incidence of chronic GvHD was low with 27%. Only one treatment-related death was because of GvHD (6%), and the overall TRM was 17%. A similar modified TBI regimen with busulfan and cyclophosphamide, but without any T-cell manipulation followed by allogeneic stem cell transplantation, was first evaluated by the Seattle group who reported a day 100 mortality of 43%. 22 We used this conditioning regimen with modified total body irradiation with lung and liver shielding (total marrow irradiation) in combination with busulfan and cyclophosphamide because a high percentage of complete responses was observed in a phase II trial followed by autologous transplantation. 27 Achieving CR after autologous or allogeneic transplantation is a major obstacle for longterm disease-free survival. 5, 22 In our study, 53% of the patients achieved a CR after allogeneic transplantation, which could be enhanced by donor lymphocyte infusion to 67%. This rate of CR is quite high considering a stringent definition for CR with negative immunofixation. For patients with CR after allografting, the 6 year probability Years after transplantation Figure 4 Probability of being in CR after allogeneic transplantation, donor-lymphocyte infusion or salvage dose-reduced allograft.
Allografting in multiple myeloma with ATG N Kröger et al of disease-free survival is 46%, which is comparable to the results of a large EBMT study, reporting a 34% diseasefree survival at 6 years for patients with CR. 1 The most surprising and encouraging result of our study is the estimated overall survival at 6 years of 77%. The EBMT and the Seattle group reported a 32 and 24% overall survival at 3 and 4 years, respectively. 1, 22 Apart from the lower TRM in our study, the high overall survival may also result from an effective salvage strategy with adoptive immunotherapy. So far only one out of six relapsed patients has died because of PD. Four of six relapsed patients received immunotherapy with either escalating donor-lymphocyte infusion or salvage with a nonmyeloablative allograft from the same donor. All four patients are alive after a median of 27 months after relapse, two of them in CR. Therefore, the probability of being in CR at 6 years is 62% (see Figure 4) . This proven graft vs myeloma effect of allogeneic T cells and the introduction of less toxic nonmyeloablative conditioning regimens for allogeneic transplantation should offer new therapeutic approaches towards a better treatment of multiple myeloma. Recently, encouraging results of dose-reduced conditioning followed by allogeneic stem cell transplantation even with unrelated donors have been reported. However, the follow-up of these studies are too short to draw any conclusions of longterm freedom of disease. [11] [12] [13] 28 We conclude that the conditioning regimen with modified TBI, busulfan and cyclophosphamide and anti-thymocyte globulin is able to induce a high CR rate after allogeneic stem cell transplantation with low rate of severe GvHD. Adoptive immunotherapies for patients with incomplete response or relapse after transplantation should be incorporated to increase the rate of CR and ensure long-term survival from this otherwise fatal disease.
